WaveMan
WaveMan · Company
GRTX · Galera Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

GRTX Galera Therapeutics (GRTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001563577
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · no price filed

Galera Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Galera Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Sorensen Mel
President and CEO
SELL
2025-11-24 SECtraded 2025-11-20
70,000
$1.4K
n/a
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Aug 16, 2024.
  • The trade is 35.9% of the 195,029 shares held after it.
  • No other insider sold within 30 days.
Insider activity: President and CEO Sorensen Mel sold about $1.4K of GRTX on Nov 20, 2025, the largest insider sale at the company since 2024.
CHANG NANCY T
Director
BUY
2025-01-02 SECtraded 2024-12-30
7,644,932
$535.1K
n/a
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 7,644,932 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Director CHANG NANCY T bought about $535.1K of GRTX on Dec 30, 2024, the largest insider purchase at the company on our record.
Sorensen Mel
President and CEO
SELL
2024-08-20 SECtraded 2024-08-16
67,015
$4.7K
n/a
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Mar 10, 2023.
  • The trade is 25.3% of the 265,029 shares held after it.
  • No other insider sold within 30 days.
Insider activity: President and CEO Sorensen Mel sold about $4.7K of GRTX on Aug 16, 2024.
Schneid Yair
BUY
2024-05-01 SECtraded 2024-04-19
100
$19
n/a
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 buys), the last on Apr 18, 2024.
  • +0.0% median (+0.0% mean) 90-day return after 9 previous buys.
  • The trade is 0.0% of the 10,723,710 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Insider Schneid Yair bought about $19 of GRTX on Apr 19, 2024.
Schneid Yair
BUY
2024-05-01 SECtraded 2024-04-19
314
$60
n/a
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 buys), the last on Apr 18, 2024.
  • +0.0% median (+0.0% mean) 90-day return after 9 previous buys.
  • The trade is 0.0% of the 10,724,024 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Insider Schneid Yair bought about $60 of GRTX on Apr 19, 2024.
41 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 36 more transactions and use the screener and CSV export. We store only your email; there is no password.
The situation: each line is one rule over one dataset
Parvinder Singh Hyare disclosed a 5%+ stake (6.65%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch GRTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns GRTX: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in GRTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Parvinder Singh Hyare
Activist 13D · 2026-06-11
6.65%
Emerald Bioventures, LLC
Activist 13D · 2026-04-27
26.5%
Timothy Opler
Activist 13D · 2026-04-27
26.5%
CHANG NANCY T
Activist 13D · 2026-04-10
5.9%

GRTX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
5 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
0 active
1
Phase 3
0 active
2
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · J. Mel Sorensen, M.D.
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$747.8K
$739.0K
$408.1K
-85%
n/a
2024
$633.3K
$611.5K
$631.8K
-68%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

GRTX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
+2,156%
TTM net income over average of 2025-03-31 and 2026-03-31
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-38.8%
operating income (EBIT proxy) over average of 2025-03-31 and 2026-03-31 minus current liabilities
P/E, trailing
25.44x
close 2026-07-20 over four quarters of diluted EPS, 2025-04-01 to 2026-03-31
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-07-20. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$2.5M-$20.2M-$49.3M-$51.2M
Net income$149.0M-$19.0M-$59.1M-$62.2M
EPS (diluted)0.64-0.34-1.33n/a
Operating cash flow-$6.0M-$12.1M-$44.8M-$43.4M
Cash$6.4M$8.3M$18.3M$4.3M
SEC XBRL, fiscal years, as known on 2026-10-28

GRTX Stock Sonar score 1/7 axes

Find similar shapesCompare
Profitability
80
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets+2156% · 100 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-38.8% · 59 pct, sector of 576
6 not measured: Financial health, Growth, Insider conviction, Institutional and government, Risk and compliance, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • Risk and compliance needs 1 of 4 inputs, 0 present: needs two 10-Ks with a Risk Factors section (not 20-F filers or stubs); no short interest or no free float on file; revenue under $50M or not filed, so a count cannot be scaled to size
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

1 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies